Context Therapeutics (NASDAQ:CNTX) Coverage Initiated by Analysts at D. Boral Capital

Stock analysts at D. Boral Capital started coverage on shares of Context Therapeutics (NASDAQ:CNTX) in a research note issued to investors on Monday, MarketBeat Ratings reports. The firm set a “buy” rating and a $9.00 price target on the stock.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $6.00 price objective on shares of Context Therapeutics in a research report on Monday, September 23rd. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $6.80.

Context Therapeutics Trading Up 0.7 %

NASDAQ CNTX opened at $1.47 on Monday. The firm has a market capitalization of $110.25 million, a P/E ratio of -1.62 and a beta of 2.25. The firm’s fifty day moving average price is $1.97 and its two-hundred day moving average price is $2.08. Context Therapeutics has a 1 year low of $0.77 and a 1 year high of $2.75.

Context Therapeutics (NASDAQ:CNTX) last issued its earnings results on Wednesday, November 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.11). On average, research analysts anticipate that Context Therapeutics will post -0.51 EPS for the current fiscal year.

Institutional Investors Weigh In On Context Therapeutics

Several hedge funds have recently bought and sold shares of CNTX. Y Intercept Hong Kong Ltd acquired a new stake in shares of Context Therapeutics during the third quarter worth $89,000. Renaissance Technologies LLC increased its position in Context Therapeutics by 63.4% during the second quarter. Renaissance Technologies LLC now owns 65,200 shares of the company’s stock worth $131,000 after acquiring an additional 25,300 shares during the period. State Street Corp raised its stake in Context Therapeutics by 21.5% in the 3rd quarter. State Street Corp now owns 111,907 shares of the company’s stock worth $219,000 after purchasing an additional 19,800 shares in the last quarter. Opaleye Management Inc. raised its stake in Context Therapeutics by 13.7% in the 1st quarter. Opaleye Management Inc. now owns 1,108,357 shares of the company’s stock worth $1,530,000 after purchasing an additional 133,357 shares in the last quarter. Finally, Affinity Asset Advisors LLC boosted its holdings in Context Therapeutics by 392.4% in the 2nd quarter. Affinity Asset Advisors LLC now owns 1,619,140 shares of the company’s stock valued at $3,246,000 after purchasing an additional 1,290,323 shares during the period. 14.03% of the stock is currently owned by institutional investors and hedge funds.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.